Computerized clinical decision support improves warfarin management and decreases recurrent venous thromboembolism

Managing warfarin therapy requires precise adjustments to maintain therapeutic levels. Prior research has shown that variability in international normalized ratio (INR) measurements can lead to complications like bleeding or thrombosis. No prior work had resolved how digital tools might influence these outcomes. This gap motivated the exploration of computerized clinical decision support (CDS) systems. It was already known that manual dose adjustments often result in suboptimal INR control. However, the extent to which CDS could improve this remained uncertain. That uncertainty drove the need for a large-scale evaluation of CDS impact. This study aimed to investigate whether CDS could enhance warfarin management in a real-world clinical setting.

The aim of this study was to evaluate the impact of implementing a computerized clinical decision support system on warfarin management. The specific problem addressed was the high variability in INR measurements and the associated risks of bleeding or thrombosis. The motivation stemmed from the need to improve patient outcomes through more consistent anticoagulation control. Prior approaches lacked the precision offered by algorithmic dose adjustments. This study sought to determine whether CDS could reduce INR variability and improve time in therapeutic range (TTR). The health system's need for scalable solutions led to the implementation and evaluation of CDS. Researchers focused on outcomes like TTR, bleeding events, and hospital utilization. The goal was to assess whether CDS could lead to safer and more effective warfarin therapy.

The study compared warfarin management metrics before and after the implementation of a computerized clinical decision support (CDS) system. A total of 2591 patients on long-term anticoagulation were included in the analysis. Researchers measured time in therapeutic range (TTR) and international normalized ratio (INR) variability as primary outcomes. They also tracked major bleeding events and thrombosis occurrences. The study used a before-and-after design with no control group. Data were collected from electronic health records across a large healthcare system. Statistical methods included relative risk calculations and hypothesis testing. The analysis focused on changes in clinical outcomes following CDS implementation.

Implementation of the CDS system led to a statistically significant increase in time in therapeutic range (TTR), from 63.99% to 65.13% (P = .04). The proportion of out-of-range INRs decreased from 42.39% to 39.97% (P < .001). Venous thromboembolism events were reduced by 59% (relative risk 0.41; P < .001). Emergency department visits decreased by 38% (relative risk 0.62; P < .001). Hospitalization rates also dropped by 38% (relative risk 0.62; P < .001). However, major hemorrhage events increased by 42% (relative risk 1.42; P = .01). These findings suggest that CDS improved INR control and reduced thrombotic events. The observed rise in bleeding events indicates a trade-off in safety outcomes.

The authors reported that CDS implementation was associated with improved time in therapeutic range and reduced INR variability in a large cohort of patients on warfarin. They observed a decrease in venous thromboembolism, emergency department visits, and hospitalizations following the introduction of CDS. However, they also noted an increase in major hemorrhage events. These findings suggest that CDS may enhance warfarin management in clinical practice. The observed improvements in TTR and thrombosis rates support the use of CDS in anticoagulation clinics. The increase in bleeding events highlights the need for continued monitoring. The authors propose that CDS can contribute to safer and more consistent warfarin therapy. They suggest that further investigation is needed to understand the mechanisms behind the observed outcomes.